Two in vitro studies credited by the company found effects on gut bacteria and satiety hormones. The lead researcher says human trials are still needed.
Recap by typeshit. Full story at Nutraceutical Business Review.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
A TriNetX analysis of over a million IBD patients was presented at the ASCO Breakthrough Meeting. ASCO's chief medical officer called the evidence preliminary.
People who used a wellness app or a medically tailored meal plan after quitting regained 3% of lost weight, versus 10% for those who used neither.
Loading…